Charles River Laboratories International (CRL) Faces Biotech R&D Spending Headwinds

1 hour ago 2

Attiya Zainib

Thu, March 5, 2026 astatine 9:34 AM CST 3 min read

Invesco Ltd‘s “Small Cap Value Fund” released its Q4 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The Invesco Small Cap Value Fund reported beardown results for Q4 2025, outperforming its Russell 2000 Value Index benchmark arsenic Class A shares delivered a quarterly instrumentality of 6.79%, compared to the benchmark’s 3.26%, with banal enactment successful the Information Technology assemblage contributing astir 2.90% to comparative show portion wellness attraction and financials detracted. For the afloat year, the money generated a 17.64% instrumentality versus 12.59% for the Russell 2000 Value Index. Management maintained greater vulnerability to economically delicate stocks and emphasized that small-cap worth equities stay attractively priced, noting that the Russell 2000 Value Index continues to commercialized astatine a humanities P/E discount comparative to the S&P 500, indicating compelling semipermanent superior appreciation potential. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its fourth-quarter 2025 capitalist letter, Invesco Small Cap Value Fund highlighted stocks similar Charles River Laboratories International, Inc. (NYSE:CRL). Charles River Laboratories International, Inc. (NYSE:CRL) provides cause discovery, development, and manufacturing enactment services to pharmaceutical and biotechnology companies worldwide. The one-month instrumentality of Charles River Laboratories International, Inc. (NYSE:CRL) was -2% portion its shares traded betwixt $91.86 and $228.88 implicit the past 52 weeks. On March 04, 2026, Charles River Laboratories International, Inc. (NYSE:CRL) banal closed astatine astir $179.58 per share, with a marketplace capitalization of astir $8.86 billion.

Invesco Small Cap Value Fund stated the pursuing regarding Charles River Laboratories International, Inc. (NYSE:CRL) in its Q4 2025 capitalist letter:

Charles River Laboratories International, Inc. (NYSE:CRL): This starring declaration probe enactment (CRO) supports the discovery, improvement and harmless manufacture of caller drugs, biologics, vaccines and medical devices. It has a diversified portfolio with vulnerability to precocious maturation therapeutic areas. Slower spending connected biotech and pharma probe and improvement has been a headwind to the stock, which gave america an accidental to put astatine what we saw arsenic an charismatic discount to our estimate of intrinsic value.

Charles River Laboratories International, Inc. (CRL) Faces Biotech R&D Spending Headwinds

Charles River Laboratories International, Inc. (NYSE:CRL) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. As per our database, 53 hedge money portfolios held Charles River Laboratories International, Inc. (NYSE:CRL) at the extremity of the 4th quarter, which was 50 successful the erstwhile quarter. While we admit the hazard and imaginable of Charles River Laboratories International, Inc. (NYSE:CRL) as an investment, our condemnation lies successful the content that immoderate AI stocks clasp greater committedness for delivering higher returns and doing truthful wrong a shorter clip frame. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article